X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (73) 73
male (59) 59
female (57) 57
index medicus (53) 53
oncology (53) 53
aged (50) 50
middle aged (48) 48
apparatus specially adapted for the manufacture of carbonfilaments (44) 44
chemical features in the manufacture of artificial filaments,threads, fibres, bristles or ribbons (44) 44
natural or artificial threads or fibres (44) 44
paper (44) 44
spinning (44) 44
textiles (44) 44
general tagging of cross-sectional technologies spanning over several sections of the ipc (43) 43
general tagging of new technological developments (43) 43
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (43) 43
lung neoplasms - drug therapy (37) 37
technical subjects covered by former us classification (36) 36
technical subjects covered by former uspc (36) 36
carcinoma, non-small-cell lung - drug therapy (28) 28
lung neoplasms - genetics (28) 28
aged, 80 and over (27) 27
gefitinib (26) 26
flexible materials not otherwise provided for (25) 25
laundering (25) 25
lung neoplasms - pathology (25) 25
respiratory system (25) 25
treatment of textiles or the like (25) 25
cancer (24) 24
receptor, epidermal growth factor - genetics (24) 24
adult (23) 23
chemotherapy (23) 23
carcinoma, non-small-cell lung - genetics (20) 20
mutation (20) 20
retrospective studies (20) 20
lung cancer, non-small cell (19) 19
mechanical methods or apparatus in the manufacture ofartificial filaments, threads, fibres, bristles orribbons (19) 19
erlotinib (18) 18
treatment outcome (18) 18
blasting (17) 17
heating (17) 17
lighting (17) 17
mechanical engineering (17) 17
non-small cell lung cancer (17) 17
protein kinase inhibitors - therapeutic use (17) 17
weapons (17) 17
carcinoma, non-small-cell lung - pathology (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
lung neoplasms - mortality (15) 15
treatment, not provided for elsewhere in class d06, of fibres, threads, yarns,fabrics, feathers, or fibrous goods made from such materials (15) 15
carcinoma, non-small-cell lung - mortality (14) 14
egfr mutation (14) 14
adenocarcinoma (13) 13
docetaxel (13) 13
quinazolines - therapeutic use (13) 13
growth-factor receptor (12) 12
neoplasm staging (12) 12
prognosis (12) 12
electricity (11) 11
open-label (11) 11
receptor, epidermal growth factor - antagonists & inhibitors (11) 11
t790m (11) 11
acquired-resistance (10) 10
adenocarcinoma - drug therapy (10) 10
analysis (10) 10
bevacizumab (10) 10
chemistry (10) 10
details or accessories of furnaces, kilns, ovens, or retorts,in so far as they are of kinds occurring in more than one kindof furnace (10) 10
finishing, dressing, tentering or stretching textile fabrics (10) 10
furnaces (10) 10
furnaces, kilns, ovens, or retorts in general (10) 10
genetic aspects (10) 10
kilns (10) 10
lung cancer (10) 10
metallurgy (10) 10
mutation - genetics (10) 10
open sintering or like apparatus (10) 10
ovens (10) 10
retorts (10) 10
1st-line treatment (9) 9
adenocarcinoma - genetics (9) 9
antineoplastic agents - therapeutic use (9) 9
conversion or distribution of electric power (9) 9
generation (9) 9
performing operations (9) 9
therapy (9) 9
transporting (9) 9
animal and vegetable oils, fats, fatty substances and waxes (8) 8
cancer research (8) 8
candles (8) 8
care and treatment (8) 8
detergents (8) 8
efficacy (8) 8
epidermal growth factor (8) 8
erlotinib hydrochloride (8) 8
essential oils (8) 8
fats, oils or fatty acids by chemical modification of fats,oils, or fatty acids obtained therefrom (8) 8
fatty acids from fats, oils or waxes (8) 8
fatty acids therefrom (8) 8
human necessities (8) 8
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (201) 201
French (26) 26
Japanese (18) 18
Chinese (14) 14
German (12) 12
Korean (4) 4
Portuguese (2) 2
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 47, pp. 28292 - 28293
Journal Article
Oncotarget, ISSN 1949-2553, 03/2018, Volume 9, Issue 17, p. 13474
The CDK8/19 kinase module comprises a subcomplex that interacts with the Mediator complex and regulates gene expression through phosphorylation of... 
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54036
Hepatocellular carcinoma is one of the most common cancers worldwide. During tumorigenesis, tumor suppressor and cancer-related genes are commonly silenced by... 
CANCER-CELLS | G ARREST | HEPATOCELLULAR-CARCINOMA | IN-VITRO | ACTIVATION | MULTIDISCIPLINARY SCIENCES | CYCLE ARREST | HEPG2 CELLS | METHYLATION INHIBITOR | INDUCTION | EXPRESSION | Phosphorylation | Apoptosis - drug effects | Humans | Liver Neoplasms - drug therapy | Cytidine - pharmacology | Carcinoma, Hepatocellular - enzymology | Cytidine - analogs & derivatives | DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors | Hep G2 Cells | Carcinoma, Hepatocellular - drug therapy | Caspases - metabolism | MAP Kinase Signaling System - drug effects | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Liver Neoplasms - enzymology | DNA Methylation - drug effects | Carcinoma | RNA | DNA | Genetic aspects | Tumor proteins | Methylation | Mitogens | Protein kinases | Cancer | Apoptosis | Cell proliferation | GTP-binding protein | eIF-2 kinase | Bax protein | Bcl-2 protein | Toxicity | p53 Protein | Cytotoxicity | Hepatocellular carcinoma | Kinases | Anticancer properties | Liver cancer | Cell growth | DNA methylation | Biocompatibility | Tumorigenesis | Inhibition | Deoxyribonucleic acid--DNA | Double-stranded RNA | Retinoblastoma protein | MAP kinase | Cyclin-dependent kinase 2 | Gene silencing | Inhibitors | Ribonucleic acids | Protein kinase | Tumor suppressor genes | Antitumor activity | DNA methyltransferase | In vivo methods and tests | Aberration | Retinoblastoma | Deoxyribonucleic acid
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2018, Volume 118, Issue 1, pp. 32 - 37
Background: Osimertinib demonstrated promising efficacy for refractory leptomeningeal metastases (LM) in preclinical data and a clinical study at 160 mg, but... 
T790M | leptomeningeal metastases | cerebrospinal fluid | osimertinib | SYSTEM | GEFITINIB | EFFICACY | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | BRAIN METASTASES | MUTATIONS | ERLOTINIB | Piperazines - administration & dosage | ErbB Receptors - cerebrospinal fluid | Lung Neoplasms - drug therapy | Prospective Studies | Humans | Middle Aged | ErbB Receptors - genetics | Carcinoma, Non-Small-Cell Lung - cerebrospinal fluid | Lung Diseases, Interstitial - chemically induced | Protein Kinase Inhibitors - adverse effects | Lung Neoplasms - cerebrospinal fluid | Meningeal Neoplasms - drug therapy | Protein Kinase Inhibitors - cerebrospinal fluid | Lung Diseases, Interstitial - epidemiology | Lung Neoplasms - genetics | Meningeal Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Piperazines - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pilot Projects | Meningeal Neoplasms - cerebrospinal fluid | Piperazines - cerebrospinal fluid | Progression-Free Survival | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Meningeal Neoplasms - secondary | Tyrosine | Epidermal growth factor receptors | Lung diseases | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Cerebrospinal fluid | Metastasis | Patients | Metastases | Epidermal growth factor | Meninges | Lesions | Protein-tyrosine kinase | Cancer | Clinical Study
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 08/2018, Volume 115, Issue 33, p. E7776
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 08/2018, Volume 115, Issue 33, pp. E7776 - E7785
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2015, Volume 75, Issue 6, pp. 1261 - 1266
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0120545
Cholangiocarcinoma (CCA) is a cancer arising from the neoplastic transformation of cholangiocytes. During tumorigenesis, tumor suppressor and cancer-related... 
CANCER-CELLS | TARGET | DRUG | APOPTOSIS | DECITABINE | OVEREXPRESSION | IN-VITRO | MULTIDISCIPLINARY SCIENCES | GENES | EXPRESSION | CARCINOMA | Apoptosis - drug effects | Humans | Cytidine - pharmacology | Cytidine - analogs & derivatives | DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors | Gene Knockdown Techniques | DNA (Cytosine-5-)-Methyltransferases - metabolism | Dose-Response Relationship, Drug | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cell Survival - drug effects | DNA (Cytosine-5-)-Methyltransferase 1 | DNA (Cytosine-5-)-Methyltransferases - deficiency | Enzyme Inhibitors - pharmacology | beta Catenin - metabolism | Up-Regulation - drug effects | DNA (Cytosine-5-)-Methyltransferases - genetics | Cholangiocarcinoma - pathology | Wnt Signaling Pathway - drug effects | Cell Line, Tumor | CpG Islands - genetics | Cell Proliferation - drug effects | Bile Duct Neoplasms - pathology | DNA Damage | DNA Methylation - drug effects | Chemotherapy | Analysis | Transferases | DNA | Biochemistry | Genetic aspects | Methylation | Cancer | Apoptosis | Transformation | Childrens health | Cytotoxicity | Cancer therapies | Anticancer properties | Proteins | Liver cancer | Demethylation | Signal transduction | Cell growth | Cell adhesion | Genetics | Biocompatibility | Tumorigenesis | Deoxyribonucleic acid--DNA | Medical research | Mortality | DNMT1 protein | Bioavailability | Gene silencing | Pathology | Inhibitors | DNA methyltransferase | Aberration | Wnt protein | Transcription | Toxicity | Leukemia | Genes | Gene regulation | Oncology | Hepatocellular carcinoma | Kinases | β-catenin | DNA methylation | Tumor necrosis factor-TNF | Pharmaceutical sciences | Cholangiocarcinoma | Pharmacology | Biological activity | Signaling | Cell death | Medical prognosis | Cell lines | Epigenetics | Tumor suppressor genes | Antitumor activity | In vivo methods and tests | Tumors | Deoxyribonucleic acid
Journal Article
Cancer, ISSN 0008-543X, 12/2013, Volume 119, Issue 24, pp. 4325 - 4332
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2015, Volume 76, Issue 4, pp. 835 - 841
Efficacies of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung... 
EGFR mutation | Acquired resistance | Medicine & Public Health | EGFR-TKI rechallenge | Oncology | Cancer Research | T790M | Pharmacology/Toxicology | Bevacizumab | 1ST-LINE TREATMENT | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | GEFITINIB RESISTANCE | CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | COMPLEX MUTATIONS | GENE | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Angiogenesis Inhibitors - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Quinazolines - administration & dosage | Lung - metabolism | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Erlotinib Hydrochloride - adverse effects | Lung - pathology | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Erlotinib Hydrochloride - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Lung - drug effects | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug Monitoring | Amino Acid Substitution | Hypertension | Lung cancer, Small cell | Angiogenesis inhibitors | Lung cancer, Non-small cell | Anemia
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2018, Volume 18, Issue 1, pp. 946 - 6
Journal Article
BMC Cancer, ISSN 1471-2407, 11/2015, Volume 15, Issue 1, p. 908
Background: The aim of this study was to detect the epidermal growth factor receptor (EGFR)-activating mutations and other oncogene alterations in patients... 
Acquired resistance | Epidermal growth factor | Next-generation sequencing | Tyrosine kinase inhibitor | ADENOCARCINOMA | ACQUIRED-RESISTANCE | C-KIT |